Investors

Shield Therapeutics is well positioned to become a fast growing, independent, international specialty pharmaceutical company.

Why invest in Shield Therapeutics?

Shield has transformed from a development-focused, privately owned company into a PLC with increasingly commercially focused, customer-facing organisation set up to sell our innovative and value-added specialty pharmaceuticals that solve patients’ unmet medical needs.

£500m+

Annual Revenue

Targeted for Feraccru

£200m+

Annual Revenue

Targeted for PT20

£60m

Amount Raised

Since 2010

London, UK

120 New Cavendish Street
London
W1W 6XX

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Munich, Germany

München 5 Höfe
Theatinerstrasse 11
DE- 80333 München

t+49 (0) 89 710 42 2246

einfo.de@shieldtx.com